Skip to main content

Table 1 Patient demographics and baseline clinical characteristics

From: Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia

Parameter

No. of subjects (%)*

N

240

Mean age

 

   Years, SD

43.9 (10.9)

Gender

 

   Male

156 (65.0%)

   Female

84 (35.0%)

Race

 

   Asian

1 (0.4%)

   Black or African American

151 (62.9%)

   Native Hawaiian or other Pacific Islander

1 (0.4%)

   White

80 (33.3%)

   Other

7 (2.9%)

DSM-IV Schizophrenia subtype diagnosis

 

   295.10 Disorganized type

4 (1.7%)

   295.20 Catatonic type

0

   295.30 Paranoid type

125 (52.1%)

   295.60 Residual type

2 (0.8%)

   295.70 Schizoaffective disorder

89 (37.1%)

   295.90 Undifferentiated type

21 (8.8%)

Preswitch antipsychotic agent at study start

 

   Quetiapine

62 (25.8%)

   Risperidone

51 (21.3%)

   Aripiprazole

44 (18.3%)

   Ziprasidone

27 (11.3%)

   Olanzapine

24 (10.0%)

   Paliperidone

9 (3.8%)

   Iloperidone

4 (1.7%)

   Asenapine

2 (0.8%)

   First-generation antipsychotic

17 (7.1%)

Treatment with concomitant lithium, valproate or lamotrigine

34 (16.2%)

Treatment with concomitant antidepressant

104 (43.3%)

Mean age (SD) at initial onset of schizophrenia or schizoaffective disorder, years

25.1 (9.3)

Mean positive and negative syndrome scale total score (SD)

68.9 (13.8)

Mean clinical global impression severity score (SD)

3.7 (0.5)

  1. *or as indicated.